<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363999">
  <stage>Registered</stage>
  <submitdate>5/04/2013</submitdate>
  <approvaldate>11/04/2013</approvaldate>
  <actrnumber>ACTRN12613000396729</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Kobeni (province of Hodh El Gharbi) and Timbedra (province of Echargui), Mauritania</studytitle>
    <scientifictitle>Efficacy and safety of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Kobeni (province of Hodh El Gharbi) and Timbedra (province of Echargui), Mauritania</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uncomplicated P falciparum malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cure rate in terms of adequate clinical and parasitological response following a 3 day course of artesunate/amodiaquine co-formuated in three different fixed tablet strengths containing artesunate (mg)/amodiaquine (mg) as follows: 25/67.5; 50/135, or 100/270. The tablet strength and the number of tablets to be  orally administered once a day will be based on body weight according to national treatment guideines and the dosing schedule appended to the protocol. Each daily dose will be administered under study staff supervision and patients will be followed-up for 28 days.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cure rate at day 28 after adjustment by polymerase chain reaction (PCR) to differentiate between recrudescence and new infection. </outcome>
      <timepoint>day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events as reported by patients or observed by investigators.  Clinical laboratory studies (hematology or biochemistry) may be required to confirm a diagnosis or to follow-up an adverse event.</outcome>
      <timepoint>day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>6 months and older
microscopically confirmed mono-infection with P falciparum 
parasitaemia between 250 and 100,000 asexual parasites/microliter
axillary temperature greater or equal to 37.5 degrees Celsius or history of fever within the past 24 hours
able to swallow medication
able to comply with the protocol and schedule of assessments</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO 
mixed infection with another plasmodium species detected my microscopy 
presence of severe malnutrition
presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehaydration) or other known underlying chronic or severe diseases
regualr medication tha tmight interfere with antimalrial pharmacokinetics
history of hypersensitivity reactions or contraindications to any medicines being tested or used as alternative treatments, 
positive pregnancy test or breast feeding in married women
adolecents between 12 and 18 or unmarried single women in whom pregnancy test may not be performed.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/10/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Mauritania</country>
      <state>Kobeni</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mauritania</country>
      <state>El Hodh Echargui</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Health Mauritania</primarysponsorname>
    <primarysponsoraddress>Ministry of Health 
BP 169
Nouakchott
Mauritania</primarysponsoraddress>
    <primarysponsorcountry>Mauritania</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Health Mauritania</fundingname>
      <fundingaddress>Ministry of Health 
BP 169
Nouakchott
Mauritania</fundingaddress>
      <fundingcountry>Mauritania</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organisation</fundingname>
      <fundingaddress>20 avenue Appia
CH 1211 Geneva 27
Switzerland</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a therapeutic efficacy study of artesunate-amodiaquine, the current first-line drug for the treatment of uncomplicated malaria in Mauritania.  Eligible subjects will be enrolled and treated for 3 days according to national treatment guidelines and will be followed up for 28 days. The results will be used to formulate recommendations and to enable the Minstry of Health to make informed decisions about whether the current national antimalaria treatment guidelines should be updated.  </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>World Health Organisation, Ethical Review Committee (WHO ERC)</ethicname>
      <ethicaddress>20 avenue Appia
CH 1211 Geneva 27
Switzerland</ethicaddress>
      <ethicapprovaldate>28/03/2013</ethicapprovaldate>
      <hrec>RPC563</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mamadou Dit Dialaw</name>
      <address>National Malaria Control Program
Ministry of Health
Box 169
Nouakchott
Mauritania</address>
      <phone>+222 22 11 70 31</phone>
      <fax />
      <email>mamadoutditdialawba@yahoo.fr</email>
      <country>Mauritania</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mamadou Dit Dialaw</name>
      <address>National Malaria Control Program
Ministry of Health
Box 169
Nouakchott
Mauritania</address>
      <phone>+222 22 11 70 31</phone>
      <fax />
      <email>mamadoutditdialawba@yahoo.fr</email>
      <country>Mauritania</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mamadou Dit Dialaw</name>
      <address>National Malaria Control Program
Ministry of Health
Box 169
Nouakchott
Mauritania</address>
      <phone>+222 22 11 70 31</phone>
      <fax />
      <email>mamadoutditdialawba@yahoo.fr</email>
      <country>Mauritania</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Pascal Ringwald</name>
      <address>World Health Organisation
20 avenue Appia
CH 1211 Geneva 27
Switzerland</address>
      <phone>+41 22 791 3469</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>